Adyghe Int. Sci. J. Vol. 23, No 2. P. 40–55
Global climate warming and the expansion of ragweed – new problems in the spread of allergopathology, forecasts and prevention
Shogenova Madina Sufyanovna
Chief physician, professor of Faculty Therapy of the Kabardino-Balkar University, MD, chief freelance allergist-immunologist, Hutueva Svetlana Hanafievna, Professor, Doctor of Medical Sciences, head of the allergy-immunological department Center for Allergology and Immunology, ORCID: 0000-0001-8234-6977, Author ID 979946, SPIN-код: 3668-4485, firstname.lastname@example.org
Hutueva Svetlana Hanafievna
Professor, Doctor of Medical Sciences, head of the allergy-immunological department. Center for Allergology and Immunology
Shogenova Laura Stanislavovna
Clinical resident Federal State Budgetary Institution «State Scientific Center «Institute of Immunology» of the Federal Medical and Biological Agency of Russia, Moscow
Muzhdabaeva Elena Leonidovna
Head of the Personnel Department, State Budgetary Healthcare Institution «Center of Allergology and Immunology» of the Ministry of Health of the Kabardino-Balkar Republic
Abstract. The article presents the main causes of the spread of ragweed pollen associated with global warming, describes the epidemiology, methods of control and prevention of pollen allergy, as well as modern principles of diagnosis and treatment of allergy to ragweed pollen. The main culprit of pollinosis is plant pollen. Clinical manifestations of allergy to ragweed pollen allergen are allergic rhinoconjunctivitis, bronchial asthma and, less often, contact dermatitis/urticaria. Up to 70% of patients with allergies to ragweed pollen react to products of the pumpkin family, as well as bananas, apple, apricot, etc. and this is due to the fact that these products and ragweed pollen contain similar proteins. Treatment of allergy to ragweed pollen with immunobiological and genetically engineered biological drugs effectively reduces the symptoms of allergic rhinitis throughout the pollination season.
Keywords: ambrosia, monitoring, global warming, allergodiagnostics, omalizumab
Acknowledgments: the authors are thankful to the anonymous reviewer for his valuable remakes.
The authors declare no conflict of interest.
For citation. Shogenova M. S., Hutueva S. H., Shogenova L. S., Muzhdabaeva E. L. Global climate warming and the expansion of ragweed – new problems in the spread of allergopathology, forecasts and prevention. Adyghe Int. Sci. J. 2023. Vol. 23, No. 2. P. 40–55.
DOI: https://doi.org/10.47928/1726-9946-2023-23-2-40-55, EDN: TIDIPX
The authors have read and approved the final version of the manuscript.
Submitted 17.05.2023; approved after reviewing 08.06.2023; accepted for publication 15.06.2023
© Shogenova M. S.,
Hutueva S. H.,
Shogenova L. S.,
Muzhdabaeva E. L., 2023
1. White J. F. et al. Ann Allergy Asthma Immunol. 2003;91:425– 435.
2. Chen K-W. et al. Int Arch Allergy Immunol 2018. DOI: 10.1159/000487997.
3. Taramarcaz P. et al. Swiss Med Wkly. 2015;145:w14198.
4. Ihler F et al. J Asthma Allergy. 2015;8:15–24.
5. Wurtzen P. A. et al. Diverse and highly cross-reactive T cell responses in ragweed allergic patients independent of geographical region. Allergy 2019; doi: 10.1111/all.13992.
6. El Kelish A. et al. BMC Plant Biology 2014, 14:176.
7. Kuan-Wei Chena, Laura Marusciaca, Paul Tudor Tamasa, Rudolf Valentab Carmen Panaitescua Ragweed Pollen Allergy: Burden, Characteristics, and Management of an Imported Allergen Source in Europe. Int Arch Allergy Immunol. 2018 DOI: 10.1159/000487997.
8. ATOPICA Project; Polen is in the Air Conference, 2015, Brussels. Last accessed Jan 2019: https://www.atopica.eu/index.html Published: Hamaoui-Laguel L et al. Nature Climate Change volume 5, pages 766–771 (2015).
9. Lake I. R. et al. Environ Health Perspect. 2017;125(3):385–391.
10. Corsico R. et al. Invest Allergol Clin Immunol, May-June 2000; Vol. 10, (3): 155–161.
11. Karrer G. et al. Science of the Total Environment 523 (2015) 120–128.
12. Creticos P. S. et al. Immunotherapy (2018) 10(7), 605–616.
13. Tosi A. et al. Swiss Med Wkly. 2011;141:w13253. 6. 5.
14. Taramarcaz P. et al. Swiss Med Wkly 2005;135:538–548.
15. Smiljanic K. et al. Clin Exp Allergy 2017;47:815–828.
16. Boldogh I. et al. J Clin Invest 2005;115:2169–2179.
17. Gunawan H. et al. Allergol Int 2008;57:83–91.
18. Essl F. et al. Journal of Ecology. 2015;103:1069–98.
19. WAO-ARIA-GA2LEN Agreement document on molecular allergodiagnostics.
20. Buzzulini Francesca, Da Re Mirella, Scala Enrico, Martelli Paola, Conte Mariaelisabetta, Brusca Ignazio, Villalta Danilo Evaluation of a new multiplex assay for allergy diagnosis. Clinica Chimica Acta 493. 2019, 73–78.
21. Melioli G., Bonifazi F., Bonini S., Maggi E., Mussap M., Passalacqua G., Rossi E.R., Vacca A., Canonica G.W. The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms, Italian Board for ISAC (IBI), Clin. Biochem. 44 (12) (Aug, 2011) 1005–1011, https://doi.org/10. 1016/j.clinbiochem.2011.05.007
22. Nettis E., Bonifazi F., Bonini S., Di Leo E., Maggi E., Melioli G., Passalacqua G., Senna, Triggiani M., Vacca A., Canonica G.W. Molecular diagnosis and the Italian Board for ISAC, Eur Ann Allergy Clin Immunol 46 (2), (Mar, 2014). 68–73.
23. Dushina L. V., Barycheva L. Yu., Minasyan M. M. Molecular allergodiagnostics and optimization of allergen-specific immunotherapy for sensitization to weed pollen. Medical Bulletin of the North Caucasus, 2020. Vol. 15, No. 3. Pp. 422–423.
24. Moreno C., Justicia J. L., Quiralte J., Moreno-Ancillo A., Iglesias-Cadarso A. [et al.]. Olive, grass or both? Molecular diagnosis for the allergen immunotherapy selection in polysensitized pollinic patients. Allergy. 2014;69(10):1357-1363. https://doi.org/10.1111/all.12474
25. Barycheva L. Yu., Dushina L. V., Minasyan M. M., Medvedenko Yu. N. Diagnostic value of the basophil activation test during sensitization to allergens of weeds. Medical Bulletin of the North Caucasus, 2020. Vol. 15, No. 4. Pp. 479–483
26. Casale T. B., Berstein I. L., Busse W. W. et al. Use of an antiIgE humanized monoclonal antibody in ragweed induced allergic rhinitis. J. Allergy Clin. Immunol. 1997. Vol. 100. Pp. 110–121.
27. Casale T. B., Condemi J., LaForce C. et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis. A randomized controlled trial. JAMA. 2001. Vol. 286. Pp. 2956–2967.
28. Kulichenko T. V. Omalizumab: expanding the possibilities of treatment of atopic diseases. Pediatric Pharmacology. 2009. Vol. 6, No. 3. Pp. 36–44
29. Hanf G., Noga O., O’Connor A. et al. Omalizumab inhibits allergen challengeinduced nasal response. Eur. Respir. J. 2004. Vol. 23. Pp. 414–418.
31. Ukhanova O. P., Dzhabarova A. A., Sivun I. V., Buryndina E. I. Prospects of genetic engineering therapy of severe seasonal allergic rhinitis. Bulletin of Modern Clinical Medicine, 2018. Vol. 11, No. 2. Pp. 36–40.
This work is licensed under a Creative Commons Attribution 4.0 License.